NCT07281391Recruiting
IOP Reduction in Pigmentary Glaucoma Using DSLT
Direct Selective Laser Trabeculoplasty Providing Effective Intraocular Pressure Reduction in Pigmentary Glaucoma Patients
Source: ClinicalTrials.gov · Last updated 9 Apr 2026
Brief summary (registry, in English)
This study is a single-site, single-arm, prospective, observational study of IOP reduction after DSLT. Subjects will be assessed up to 12 months post-operatively. Clinical evaluations will include IOP and number of glaucoma medications.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 45 (estimated)
- First submitted
- 20 Nov 2025
- Start date
- 19 Mar 2026
- Primary completion date
- 1 Apr 2027
- Lead sponsor
- Mann Eye Institute
- Diseases
- Glaucoma
- NCT number
- NCT07281391
What you commit to
- Study type: Observational
- Planned participants: 45
- From 19 Mar 2026 to the primary completion date, 1 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior incisional glaucoma surgery or glaucoma-related procedures in the study eye
- Prior laser trabeculoplasty \<3 years
- Prior intraocular surgery and refractive surgery, except for cataract surgery unless greater than 2 years
- Patients anticipating cataract surgery within the follow-up period
Other illness
- History of ocular inflammation and infection
Other
- All other secondary glaucoma including exfoliative
- Patients unable to have DSLT treatment
Who the study is looking for
- Adult patients with pigmentary dispersion syndrome with elevated IOP or mild to moderate (based on AAO Preferred Practice Program criteria) pigmentary glaucoma with glaucomatous optic neuropathy and corresponding visual field/RNFL loss.
- Treatment naive, or washed out IOP ranging from ≥18-34 mmHg
- Central corneal thickness (CCT) 480-600 µm
- Able to complete medication washout and follow-up
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mann Eye Institute Coordinator of this site? Confirm its status | Houston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.